University of Vermont

The University of Vermont Cancer Center

Bio for Steven Ades, M.D., MSc
Steven Ades, M.D., MSc

Steven Ades, M.D., MSc

Associate Professor of Medicine, Hematology/Oncology Division, Department of Medicine


Contact Information
E-mail: Steven.Ades@uvm.edu
Phone:
(802) 656-5487
Office Location:
University of Vermont, College of Medicine Building, Given E-214, Burlington, VT 05405

Education

1992-1996     McGill University, Montreal, Canada; MDCM
1996-1999     Queens University / Kingston General & Hotel Dieu Hosptials, Kingston, Ontario; Internal Medicine 
1989-1992     McGill University, Montreal Canada; BS

Postdoctoral Training

1999-2002     Hematology/Oncology Fellowship, Tufts University, Boston MA
2000-2002     Research Fellow, Tufts University School of Medicine, Boston, MA
2002-2005     Masters Degree in Epidemiology and Biostatistcs.

Academic Interests

These include clinical research around adjuvant treatment options for patients with esophageal and stomach cancers, supportive care for patients undergoing abdominal radiation therapy including novel combinations of antiemetics in this setting (AVERT trial: NCT00970905), and the protective impact of lipid lowering  agents called statins on the risk of venous blood clots in patients with advanced cancer. I also participate in many national cooperative group trials covering the cancer sites listed above.

Publications

Ades S. Adjuvant therapy for colon cancer in the elderly.  Oncology 23(2):162-7, 2009

Ades S, Koushik A, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, CoutlĂ©e F, Roger M, Franco E (for the Biomarkers of Cervical Cancer Risk Study Team).Selected Class I and Class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia.  Int J Cancer 122(12):2820-6, 2008.

L. E. Ferri*, S. Ades*, T. Alcindor, M.R. Chasen, V. Marcus, M. Hickeson, G. Artho, M. P. Thirlwell. Peri-Operative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: A Multi-Center Phase II Trial. Ann Oncol. 2011 Oct 29. (*Co-primary authorship Ferri & Ades)  Epub ahead of print

Ades S, Maxfield LF, Gould CJ, Jones GK, Levy SB. Selection of non-P-glycoprotein mediated high-level etoposide resistant cell lines by adriamycin with P-gp inhibitors, Int J Oncol 28(3): 747-53, 2006

For a complete list of Steven Ades' publication, please visit Google Scholar